


**Product Name** : Capmatinib  
**Cat. No.** : PC-43511  
**CAS No.** : 1029712-80-8  
**Molecular Formula** : C<sub>23</sub>H<sub>17</sub>FN<sub>6</sub>O  
**Molecular Weight** :  
**Target** : c-Met (HGFR)  
**Solubility** : DMSO: 12.66 mg/mL



## Biological Activity

Capmatinib (INCB-28060, INC-280) is a highly potent, selective, ATP competitive inhibitor of **c-MET kinase** with IC<sub>50</sub> of 0.13 nM, displays no activity against RON $\beta$ , EGFR and HER-3; inhibits c-MET phosphorylation (IC<sub>50</sub>=1 nM) in SNU-5 human gastric cancer cell line, is slightly more potent in H596 and H1437 lung cancer cell lines that express mutant c-MET due to an exon 14 deletion and a R988C mutation; inhibits c-MET phosphorylation and tumor growth in c-MET-driven mouse tumor models.

Lung Cancer  
Phase 3 Clinical

## References

- Liu X, et al. Clin Cancer Res. 2011 Nov 15;17(22):7127-38.  
Brandes F, et al. BMC Cancer. 2015 Feb 19;15:71.  
Moran-Jones K, et al. Sci Rep. 2015 Jul 3;5:11749.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com